Cosmos Health Valuation
Is V67A undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of V67A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate V67A's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate V67A's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for V67A?
Other financial metrics that can be useful for relative valuation.
What is V67A's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$11.44m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 0.4x |
Enterprise Value/EBITDA | -1.3x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does V67A's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 0.3x | ||
TLIK TELES | 0.1x | n/a | €5.8m |
HAEK HAEMATO | 0.3x | 5.7% | €88.6m |
ILM1 Medios | 0.2x | 6.2% | €411.7m |
UOM AS Latvijas Juras medicinas centrs | 0.7x | n/a | €6.9m |
V67A Cosmos Health | 0.4x | 21.5% | €11.4m |
Price-To-Sales vs Peers: V67A is expensive based on its Price-To-Sales Ratio (0.4x) compared to the peer average (0.3x).
Price to Earnings Ratio vs Industry
How does V67A's PE Ratio compare vs other companies in the DE Healthcare Industry?
Price-To-Sales vs Industry: V67A is good value based on its Price-To-Sales Ratio (0.4x) compared to the European Healthcare industry average (0.7x).
Price to Sales Ratio vs Fair Ratio
What is V67A's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 0.4x |
Fair PS Ratio | 0.4x |
Price-To-Sales vs Fair Ratio: V67A is good value based on its Price-To-Sales Ratio (0.4x) compared to the estimated Fair Price-To-Sales Ratio (0.4x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.